WillItSurvive
Pharma and healthcare groups · China

Aier Eye Hospital Group

Aier runs China's largest ophthalmology hospital chain: 391 hospitals, 272 clinics.

Protection under test
Assessed 25 July 2026 · Evidence as of 25 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 25 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: H1 2026 earnings report, which will show whether the FY2025 profit decline continues after the CNY 524M back-tax payment
The call

Aier's hospital network and insurance ties keep public and private rivals out, but its first-ever profit decline and an insurance-fraud scandal near its founder are open questions for 2026.

Aier Eye Hospital Group operates nearly 400 hospitals and clinics across China, performing surgeries and eye care that generate cash payments from patients. It is hard to copy because building a national network of licensed hospitals takes decades, requires trained eye surgeons, and locks in insurance payments, but smaller private rivals like He Eye exist and China's public hospitals (though government-run) could theoretically compete. The single biggest threat is regulatory: a fraud scandal linked to the founder in early 2026, plus questions about how Aier bills insurance, could trigger a formal investigation that would directly hurt the company's ability to get paid by insurers and damage investor confidence within months.

Why
01
AI pressure: None apparent. AI fundus-screening tools speed diagnosis and referrals but cannot perform surgery, so they feed Aier's pipeline instead of replacing it. Could AI do the core job? Unlikely.
02
Bigger players: Fudan Eye & ENT Hospital, Zhongshan Ophthalmic Center (public academic hospitals). These elite public hospitals are bigger names but are funded and mandated to stay centralized, so they cannot copy Aier's distributed cash-pay clinic model. Could a giant copy it? No, they are blocked.
03
What protects it. 391 licensed hospitals plus insurance-reimbursement relationships, a trained surgeon pipeline, and 20 years of clinical data across China.
What would change this call
China regulators formally investigate Aier's listed entity (not just founder Chen Bang's other holdings) over insurance billing within 12 months. Would show the fraud scandal has moved from reputational overhang to direct legal and financial risk for shareholders.
FY2026 annual report shows a second consecutive year of net profit decline alongside revenue growth. Would confirm margin compression is structural rather than a one-off tax event from the CNY 524 million back-tax payment.
Aier files a formal Hong Kong secondary-listing prospectus within 6 months. Would show management is raising fresh capital, possibly to offset weakening domestic profitability.
Key numbers
  • FY2025 net profit fell 8.88% YoY despite 6.53% revenue growth (2026-05-21)
  • Q1 2026 net profit up 12.46% YoY after CNY 524M back-tax payment (2026-05-21)
  • Market cap dropped over 70% from 2021 peak, below CNY 100B (2026-03-09)
Named risks
  • Insurance-fraud scrutiny of founder Chen Bang could widen to Aier's own listed-entity billing practices. Severity: high
  • FY2025 marked first-ever annual net profit decline (-8.88%) despite revenue growth. Severity: medium
  • Q1 2026 profit growth followed a CNY 524 million back-tax payment, sustainability unclear. Severity: medium
  • October 2025 charitable-donation recycling allegations involving Aier remain under scrutiny. Severity: medium
  • Market cap down over 70% from 2021 peak signals sustained investor caution. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
C-MER Medical (Hong Kong)losing toAier's revenue and profit over 10x C-MER's, trading at 30x vs C-MER's 15x earnings as of Apr 2026
He Eye Hospital Groupcontestingsmaller domestic private ophthalmology chain competing in China market, referenced Feb 2026
Huaxia Eye Hospital Groupcontestingnamed alongside Aier in Oct 2025 charitable-donation recycling allegations
Fudan Eye and ENT Hospital, Zhongshan Ophthalmic Centercontestingelite public academic hospitals retain tertiary case share but barred from Aier's cash-pay retail model by funding mandate
Questions people ask
Is Aier Eye Hospital Group profitable in 2026?
Yes but pressured. FY2025 net profit was CNY 3.24 billion, down 8.88% YoY, the first annual profit decline since Aier's 2009 IPO despite 6.53% revenue growth. Q1 2026 net profit rose 12.46% to CNY 1.18 billion, but that followed a CNY 524 million back-tax payment disclosed in May 2026, clouding the rebound's sustainability.
Could AI replace Aier Eye Hospital Group's business?
No. AI aids screening, such as a deep-learning tool with MiiS that raised diabetic-retinopathy detection accuracy to 93% on a 5,000-patient Aier dataset, but licensed surgery, hospital operating rooms, and insurance-reimbursement relationships across Aier's 391 hospitals plus 272 clinics as of end-2025 cannot be replicated by AI alone.
Who is Aier Eye Hospital Group's biggest competitor?
Aier is the world's largest ophthalmology hospital group by network size as of October 2025. Domestic private rivals He Eye Hospital Group and Huaxia Eye Hospital Group are far smaller, and Hong Kong-listed C-MER Medical has under one-tenth Aier's revenue and profit as of April 2026, per third-party analysis.
Who owns Aier Eye Hospital Group?
Aier was founded January 24, 2003 by Chen Bang with Li Li, and Chen Bang remains controlling shareholder as of February 2026. It has been publicly traded on the Shenzhen Stock Exchange under ticker 300015 since its 2009 IPO, China's first publicly listed medical institution.
Is Aier Eye Hospital Group planning a Hong Kong listing?
Reports from March and April 2026 say Aier is exploring or actively seeking a secondary Hong Kong listing for international growth, though the company has not officially confirmed this; its chairman said as recently as May 2024 there were no immediate plans.
Why did Aier Eye Hospital Group's stock fall so much?
Aier's market capitalization dropped below CNY 100 billion by March 2026, more than 70% off its 2021 peak, amid a first-ever annual net profit decline in FY2025, a CNY 524 million back-tax payment, and insurance-fraud allegations touching the founder disclosed in February 2026.
Timeline
  • 2026-05-21FY2025 results: revenue CNY 22.35B, net profit CNY 3.24B down 8.88%, CNY 524M back-tax payment disclosed
  • 2026-04-30Reported actively seeking Hong Kong listing; network reaches 391 hospitals, 272 clinics, 179 overseas centers
  • 2026-04-23Q1 2026 summary published citing advancing digital and AI strategy
  • 2026-03-09Market cap falls below CNY 100 billion, down over 70% from 2021 peak amid HK listing rumors
  • 2026-02-08Insurance-fraud reporting links founder Chen Bang to Hubei psychiatric hospitals; Aier distances itself
  • 2025-10-27FY2024 results reported: revenue CNY 20.98B up 3.02%, net profit up 5.87%
  • 2025-10-01Described as world's largest ophthalmology hospital group by network size
  • 2022-09Raised CNY 3.5 billion via private placement led by ICBC Credit Suisse Asset Management
  • 2009IPO on Shenzhen Stock Exchange as China's first publicly listed medical institution
  • 2003-01-24Founded by Chen Bang with Li Li
Revision history
25 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
SolventumNovo NordiskBaxter International
More in Pharma and healthcare groups →
Sources